{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":5,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":90,"n_cols":5,"rows_kept":90,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[16,2,16,3],[18,2,18,3],[18,4,18,5],[19,2,19,3],[19,4,19,5],[20,2,20,3],[20,4,20,5],[21,2,21,3],[22,2,22,3],[23,2,23,3],[24,2,24,3],[25,2,25,3],[26,2,26,3],[28,2,28,3],[29,2,29,3],[33,2,33,3],[35,2,35,3],[35,4,35,5],[36,2,36,3],[36,4,36,5],[37,2,37,3],[39,2,39,3],[42,2,42,3],[43,2,43,3],[44,2,44,3],[45,2,45,3],[46,2,46,3],[47,2,47,3],[50,2,50,3],[57,2,57,3],[57,4,57,5],[58,2,58,3],[58,4,58,5],[59,2,59,3],[59,4,59,5],[60,2,60,3],[61,2,61,3],[62,2,62,3],[63,2,63,3],[64,2,64,3],[65,2,65,3],[66,2,66,3],[67,2,67,3],[69,2,69,3],[69,4,69,5],[70,2,70,3],[70,4,70,5],[71,2,71,3],[71,4,71,5],[72,2,72,3],[74,2,74,3],[78,2,78,3],[79,2,79,3],[80,2,80,3],[82,2,82,3],[83,2,83,3],[85,2,85,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910786043603321"]
[null,null,"Autore",null,"Axelrod C. Warren"]
[null,null,"Titolo",null,"Engineering safe and secure software systems / / C. Warren Axelrod"]
[null,null,"Pubbl/distr/stampa",null,"Boston : , : Artech House, , [2013]"]
[{"$nulls":4},"[Piscataqay, New Jersey] : , : IEEE Xplore, , [2012]"]
[null,null,"ISBN",null,"1-60807-473-0"]
[null,null,"Descrizione fisica",null,"1 online resource (349 p.)"]
[null,null,"Collana",null,"Artech House information security and privacy series"]
[null,null,"Disciplina",null,"620.001/171"]
[null,null,"Soggetti",null,"Software engineering"]
[{"$nulls":4},"Systems engineering"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"1. Introduction -- 2. Engineering Systems -- 3. Engineering Software Systems -- 4. Engineering Secure and Safe Systems, Part 1 -- 5. Secure and Safe Systems, Part 2 -- Secure and Safe Systems, Part 2 -- 6. Software Systems Security and Safety Risk -- 7. Software System Security and Safety Metrics -- 8. Software System Development Processes -- 9. Secure SSDLC Projects in Greater Detail -- 10. Safe SSDLC Projects in Greater Detail -- 11. The Economics of Software Systems' Safety and Security -- Appendices."]
[null,null,null,"Sommario/riassunto","\"This first-of-its-kind resource offers a broad and detailed understanding of software systems engineering from both security and safety perspectives. Addressing the overarching issues related to safeguarding public data and intellectual property, the book defines such terms as systems engineering, software engineering, security, and safety as precisely as possible, making clear the many distinctions, commonalities, and interdependencies among various disciplines. You explore the various approaches to risk and the generation and analysis of appropriate metrics. This unique book explains how processes relevant to the creation and operation of software systems should be determined and improved, how projects should be managed, and how products can be assured. You learn the importance of integrating safety and security into the development life cycle. Additionally, this practical volume helps identify what motivators and deterrents can be put in place in order to implement the methods that have been recommended.\""]
[null,"2.","Record Nr.",null,"UNINA9910779772803321"]
[null,null,"Autore",null,"Sherman Phillip Michael"]
[null,null,"Titolo",null,"Babel's Tower translated [[electronic resource] ] : Genesis 11 and ancient Jewish interpretation / / by Phillip Michael Sherman"]
[null,null,"Pubbl/distr/stampa",null,"Leiden ; ; Boston, : Brill, 2013"]
[null,null,"ISBN",null,"90-04-24861-7"]
[null,null,"Descrizione fisica",null,"1 online resource (377 p.)"]
[null,null,"Collana",null,"Biblical interpretation series ; ; vol. 117"]
[null,null,"Disciplina",null,"222/.110609"]
[null,null,"Soggetti",null,"Babel, Tower of"]
[{"$nulls":4},"Rabbinical literature - History and criticism"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Front Matter -- Interpretation as Translation or Exegesis and Historical Hermeneutics -- Introduction to Part I -- Return to Babel: Reading without the Canon -- Reading Babel Backwards. Canonical Foundations for Exegetical Expansion -- Introduction to Part II -- The Holy Language in the Book of Jubilees: The Tower of Babel and the Eclipse of Sacred Tradition -- Pseudo-Philo’s Biblical Antiquities: Echoes of the Tower -- Josephus and the Influence of Anxiety: Colonizing the Tower and the Politics of Dispersion -- Translated to Heaven: The Tower of Babel and Third (Greek) Baruch -- The Inner Tower: Philo and the Translation of Cultures -- Introduction to Part III -- A Just Translation: Reading the Rabbinic Babel in Genesis Rabbah -- Conclusion -- Bibliography -- Indexes."]
[null,null,null,"Sommario/riassunto","In Babel's Tower Translated , Phillip Sherman explores the narrative of Genesis 11 and its reception and interpretation in several Second Temple and Early Rabbinic texts (e.g., Jubilees, Philo, Genesis Rabbah). The account of the Tower of Babel (Genesis 11:1-9) is famously ambiguous. The meaning of the narrative and the actions of both the human characters and the Israelite deity defy any easy explanation. This work explores how changing historical and hermeneutical realities altered and shifted the meaning of the text in Jewish antiquity."]
[null,"3.","Record Nr.",null,"UNINA9910781469203321"]
[null,null,"Titolo",null,"Current issues in Romance languages : selected papers from the 29th Linguistic Symposium on Romance Languages (LSRL), Ann Arbor, 8-11 April 1999 / / edited by Teresa Satterfield, Christina Tortora, Diana Cresti"]
[null,null,"Pubbl/distr/stampa",null,"Amsterdam ; ; Philadelphia : , : J. Benjamins Pub., , 2002"]
[{"$nulls":4},"©2002"]
[null,null,"ISBN",null,"1-283-31219-0"]
[{"$nulls":4},"9786613312198"]
[{"$nulls":4},"90-272-7543-2"]
[null,null,"Descrizione fisica",null,"1 online resource  (vi, 403 pages)"]
[null,null,"Collana",null,"Amsterdam studies in the theory and history of linguistic science. Series IV, Current issues in linguistic theory, , 0304-0763 ; ; v. 220"]
[null,null,"Disciplina",null,"440"]
[null,null,"Soggetti",null,"Romance languages"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"CURRENT ISSUES IN ROMANCE LANGUAGES; Editorial page; Title page; Copyright page; Table of contents; PREFACE; ON BECOMING A CLITIC: THE  PRENOMINAL POSSESSIVE IN ROMANCE; 0. Introduction; 1. Latin roots; 2. Development from Latin; 2.1 Old French; 2.2 Old Spanish; 2.3 Italian; 3. Syntactic Representation; 4. Conclusion; REFERENCES; PRIMARY STRESS IN SPANISH; 0. Introduction; 1. Data; 2. Test; 3. Analysis; 3.1 Lexical patterns; 3.2 Quantity sensitivity; 3. 3 Falling diphthongs; 3.4 A process in change; 4. Ternary Feet; 5. Conclusion; REFERENCES; SPANISH CLAUSES WITHOUT COMPLEMENTIZER"]
[{"$nulls":4},"1. Introduction 2. Spanish clauses without complementizer; 3. On the presence or absence of the CP projection; 3.1 Topicalization; 3.2 Wh-extraction; 4. On the impossibility of a pre-verbal subject in complementizerless clauses; 5. Conclusion; REFERENCES; ON THE NATURE OF BARE NOUNS IN HAITIAN CREOLE; 1. Introduction; 2. Theoretical Background; 3. The properties of Haitian Creole bare Nouns; 4. HC bare nouns in Chierchia's typology; 5. Evidence for a null determiner in HC; 6. The syntax and semantics of the Haitian Creole null D°; REFERENCES; TOWARDS A SYNTAX OF ADULT ROOT INFINITIVES"]
[{"$nulls":4},"0. Introduction 1. Syntactic properties; 1.1 Adverb placement; 1.2 Left periphery; 1.3 Clausal structure; 2. Some differences; 2.1 Temporal interpretation; 2.2 Topic constructions; 2.3 Subject properties; 2.4 "]
[{"$nulls":4},"Infinitival raising; 3. Syntactic analysis; 4. Conclusion; REFERENCES; RE-EXAMINING SPANISH 'RESYLLABIFICATION'; 1. Introduction; 2. Data; 3. The Status of Spanish Prefixes; 4. A Theoretical Analysis of Spanish Syllabification; 5. Previous Analyses and Their Shortcomings; 6. Conclusion; REFERENCES; ON PREVERBAL SUBJECTS IN SPANISH; 0. Introduction; 1. Spanish preverbal subjects"]
[{"$nulls":4},"2. Evidence that preverbal subjects are not in topic position 3. Focus/wh-phrases; 4. Evidence that preverbal subjects are not in focus/wh- position; 5. Towards a solution; 6. Conclusions; REFERENCES; THE SEMANTICS OF SPANISH FREE RELATIVES; 1. The morphological encoding of quantificational force; 2. Indefinite FRs; 3. Definite vs. universal FRs; 4. The semantic interpretation of FRs; REFERENCES; SPLIT SUBJECT PRONOUN PARADIGMS: FEATURE GEOMETRY AND UNDER SPECIFICATION; 0. Introduction; 1. Linguistic Atlas Data; 2. How many parameters?; 3. Feature Geometry; 4.Underspecification"]
[{"$nulls":4},"4.1 The tu ~ vous split 5. Splitting the Geometry; 6. Conclusion; REFERENCES; LOCATIVE INVERSION, PP TOPICALIZATION AND THE EPP; 0. Introduction; 1. The transitivity restriction in English; 2. Agr as [+D] head in Spanish; 3. Locative subjects vs. fronted locative PPs in Spanish; 4. PP fronting in Italian; 5. Conclusion; REFERENCES; CONTRAST MAINTENANCE AND INTERVOCALIC STOP LENITION IN SPANISH AND PORTUGUESE: WHEN IS IT ALRIGHT TO LENITE?; 0. Introduction; 1. Lenition Processes; 2. The phonetic implementation of intervocalic stops in Spanish and Portuguese; 3. Experimental design; 4. Results; 5. Conclusions"]
[null,null,null,"Sommario/riassunto","This book presents an enlightening collection of papers contributing to theoretical discussions across many topics within the study of Romance Languages and Linguistics. The work originates from the 29th Linguistic Symposium on Romance Languages held in 1999 at the University of Michigan-Ann Arbor, although only a small subpart of the proceedings papers are included in this volume. The selected papers have been reworked for the current publication."]
[null,"4.","Record Nr.",null,"UNINA9910839791803321"]
[null,null,"Autore",null,"Picardi, Filippo"]
[null,null,"Titolo",null,"Morale e filosofia della morale in Erminio Juvalta / Filippo Picardi"]
[null,null,"Pubbl/distr/stampa",null,"Milano, : Marzorati, copyr. 1978"]
[null,null,"Descrizione fisica",null,"220 p. ; 24 cm"]
[null,null,"Collana",null,"Pubblicazioni dell'Istituto di filosofia, Facoltà di magistero dell'Università di Genova ; 24"]
[null,null,"Disciplina",null,"171"]
[null,null,"Locazione",null,"FLFBC"]
[null,null,"Collocazione",null,"DAM A70 PICF 01"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"5.","Record Nr.",null,"UNINA9911020083103321"]
[null,null,"Autore",null,"Corey E. J"]
[null,null,"Titolo",null,"Molecules Engineered Against Oncogenic Proteins and Cancer : Discovery, Design, and Development"]
[null,null,"Pubbl/distr/stampa",null,"Newark : , : John Wiley & Sons, Incorporated, , 2023"]
[{"$nulls":4},"©2023"]
[null,null,"ISBN",null,"9781394207145"]
[{"$nulls":4},"139420714X"]
[{"$nulls":4},"9781394207091"]
[{"$nulls":4},"1394207093"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (391 pages)"]
[null,null,"Soggetti",null,"Protein kinases - Inhibitors"]
[{"$nulls":4},"Oncogenes"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Title Page -- Copyright -- Contents -- Preface -- Chapter 1. Introduction -- 1.1 Types of Protein Kinases -- 1.2 Protein Kinase Domains -- 1.3 ATP-Binding Site -- 1.4 Types of Kinase Inhibitors -- 1.5 Brief History of Small-molecule kinase Inhibitors -- 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors -- 1.7 Approved Kinase Inhibitors -- Chapter 2. BCR-ABL Inhibitors -- 2.1 Imatinib* -- 2.2 Nilotinib* -- 2.3 Dasatinib* -- 2.4 Bosutinib* -- 2.5 Ponatinib* -- 2.6 Olvermbatinib** -- 2.7 Asciminib* -- Chapter 3. BTK Inhibitors -- 3.1 Ibrutinib* -- 3.2 Acalabrutinib* -- 3.3 Zanubrutinib* -- 3.4 Tirabrutinib** -- 3.5 Orelabrutinib** -- Chapter 4. EGFR/HER Family Inhibitors -- 4.1 Gefitinib* -- 4.2 Erlotinib * -- 4.3 Icotinib** -- 4.4 Afatinib* -- 4.5 Dacomitinib* -- 4.6 Osimertinib* -- 4.7 Mobocertinib* -- 4.8 Lapatinib* -- 4.9 Tucatinib* -- 4.10 Neratinib* -- Chapter 5. VEGFR/Multikinase Inhibitors -- 5.1 Sorafenib* -- 5.2 Regorafenib* -- 5.3 Sunitinib* -- 5.4 Pazopanib* -- 5.5 Axitinib* -- 5.6 Nintedanib* -- 5.7 Apatinib** -- 5.8 Lenvatinib* -- 5.9 Tovozanib* -- Chapter 6. CDK4/6 Inhibitors -- 6.1 Palbociclib* -- 6.2 Ribociclib* -- 6.3 Abemaciclib* -- 6.4 Trilaciclib* -- Chapter 7. JAK Inhibitors -- 7.1 Tofacitinib* -- 7.2 Baricitinib* -- 7.3 Peficitinib** -- 7.4 Upadacitinib* -- 7.5 Delgocitinib** -- 7.6 Filgotinib** -- 7.7 Abrocitinib* -- 7.8 Ruxolitinib* -- 7.9 Fedratinib* -- 7.10 Pacritinib* -- 7.11 Ritlecitinib# "]
[{"$nulls":4},"-- 7.12 Brepocitinib# -- 7.13 Ropsacitinib# -- Chapter 8. Allosteric TYK2 Inhibitors -- 8.1 Deucravacitinib* -- Chapter 9. ALK/multikinase Inhibitors -- 9.1 Crizotinib* -- 9.2 Ceritinib* -- 9.3 Alectinib* -- 9.4 Brigatinib* -- 9.5 Lorlatinib* -- Chapter 10. BRAF/Multikinase Inhibitors -- 10.1 Vemurafenib* -- 10.2 Dabrafenib* -- 10.3 Encorafenib* -- Chapter 11. MEK Inhibitors -- 11.1 Trametinib* -- 11.2 Cobimetinib*."]
[{"$nulls":4},"11.3 Binimetinib* -- 11.4 Selumetinib* -- Chapter 12. RET/Multikinase Inhibitors -- 12.1 Vandetanib* -- 12.2 Cabozantinib* -- 12.3 Selpercatinib* -- 12.4 Pralsetinib* -- Chapter 13. FGFR Inhibitors -- 13.1 Erdafitinib* -- 13.2 Pemigatinib* -- 13.3 Infigratinib* -- 13.4 Futibatinib* -- Chapter 14. PI3K Inhibitors -- 14.1 Alpelisib* -- 14.2 Idelalisib* -- 14.3 Duvelisib* -- 14.4 Umbralisib* -- 14.5 Copanlisib* -- Chapter 15. TRK/Multikinase Inhibitors -- 15.1 Larotrectinib* -- 15.2 Entrectinib* -- 15.3 Repotrectinib# -- Chapter 16. MET Inhibitors -- 16.1 Capmatinib* -- 16.2 Tepotinib* -- Chapter 17. KIT/PDGFR/Multkinase Inhibitors -- 17.1 Avapritinib* -- 17.2 Ripretinib* -- Chapter 18. FLT3 Inhibitors -- 18.1 Midostaurin* -- 18.2 Gilteritinib* -- Chapter 19. mTOR Inhibitors -- 19.1 Sirolimus* and Analogs -- Chapter 20. Other Kinase Inhibitors -- 20.1 Netarsudil* -- 20.2 Belumosudil* -- 20.3 Fostamatinib* -- 20.4 Pexidartinib* -- Chapter 21. KRAS Inhibitors -- 21.1 Sotorasib* -- 21.2 Adagrasib* -- 21.3 JDQ443# -- Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases -- 22.1 High-quality Leads -- 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors -- 22.3 Variation of Hinge-binding Nucleus -- 22.4 Macrocyclization -- 22.5 Fragment-based Approach -- 22.6 Covalent Inhibitors -- 22.7 Strategic Structural Modification of Prior Drugs -- 22.8 Exploiting Specific Kinase Pocket to Optimize Selectivity -- 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties -- Chapter 23. Targeted Molecular Anticancer Therapies - Successes and Challenges -- 23.1 The Beginning -- 23.2 Further Developments -- 23.3 Biomarker-driven Drug Development -- 23.4 Mitigation of Drug Resistance -- 23.5 Miscellaneous Approaches -- 23.6 Discovery Chemistry."]
[{"$nulls":4},"Appendix 1. First FDA Approvals by Year -- Appendix 2. Kinase/KRAS Inhibitors in Development -- Appendix 3. Visualization of Differentially Expressed Kinases in Cancer -- Appendix 4. M &amp -- A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors -- Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors -- EULA."]
[null,null,null,"Sommario/riassunto","This book provides a comprehensive examination of recent scientific advancements in cancer treatment, focusing on the development of molecular therapies targeting oncogenic proteins. Authored by E. J. Corey and Yong-Jin Wu, it explores the transformation in cancer therapy over the last 30 years through the introduction of nearly 80 FDA-approved synthetic compounds. These compounds specifically target mutated biomolecules responsible for cancer, differing significantly from older cytotoxic agents. The book discusses the role of protein kinases, a class of enzymes integral to cell growth regulation, in cancer proliferation, and highlights the pivotal scientific research enabling these breakthroughs. It is intended for researchers, medical professionals, and students interested in oncology, molecular biology, and drug development."]